Form 4: Immix Biopharma CEO Ilya Rachman Acquires Additional Shares

Sentiment:

SEC Form 4 Filing


Immix Biopharma's CEO and Chairman, Ilya Rachman, purchased 2,600 shares of common stock at $2.13 per share on June 7, 2024.

Summary

  • On June 7, 2024, Ilya Rachman, the CEO and Chairman of Immix Biopharma, Inc., acquired 2,600 shares of the company's common stock.
  • The purchase price was $2.13 per share.
  • Following this transaction, Rachman directly owns 1,136,259 shares of Immix Biopharma's common stock.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing, so the sentiment is considered neutral.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC when a company insider, such as the CEO, buys or sells shares of their company. It provides transparency to the market regarding insider transactions.

Stakeholder Impact

  • The purchase of shares by the CEO may signal confidence in the company's future prospects to shareholders.

Key Dates

DateDescription
06/07/2024Date of stock acquisition by Ilya Rachman
06/10/2024Date of signature on the Form 4 filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.